We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 29, 2021

The OncoMasTR Test Predicts Distant Recurrence in ER-Positive, HER2-Negative Early-Stage Breast Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8
Clin. Cancer Res 2021 Aug 11;[EPub Ahead of Print], M Filipits, M Rudas, V Kainz, CF Singer, F Fitzal, Z Bago-Horvath, R Greil, M Balic, P Regitnig, S Halper, W Hulla, D Egle, S Barron, T Loughman, D O'Leary, WM Gallagher, D Hlauschek, M Gnant, P Dubsky

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading